fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 100. More products

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Pharma-Amlodipine (02469030), Pharma-Amlodipine (02469049). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Amlodipine

Form:

24 of 24 products shown

12 general benefit · 1 Limited Use · 11 not a benefit

PDP-Amlodipine · DIN 02484706 · 1 mg/mL · Oral Sol

Limited Use, Reason for Use code 645, 706 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 645, 706 required
Write on scriptone applicable Reason for Use code, 645 or 706 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 645, 706
Reason for Use code 645 For patients unable to swallow or tolerate oral solid dosage forms of amlodipine. Coverage limit: LU Authorization Period: 1 year Reason for Use code 706 For pediatric patients (less than 18 years of age) where the appropriate dose cannot be achieved using a listed solid oral dosage form of amlodipine. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
PDP-Amlodipine · DIN 02484706 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 2023-04-28 Health Canada: Marketed since 2019-08-28 · brand PDP-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Solution · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 1 MG/ML · company Pendopharm division of pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PDP-Amlodipine: Formulary list price $1.17 per unit (the source does not state the unit; exact figure $1.1667). What the ministry pays, not the patient.

Ministry pays: $1.1667 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02484706)

Source record
DIN 02484706: PDP-Amlodipine Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240400176; group id 274; item number 0566; lccId 00369; manufacturer id PEN Source form: Oral Sol; strength: 1mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.1667; ministry $1.1667 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02484706 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97499
Shortage status: resolved shortage (ended August 23, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02484706
Shortage record checked October 6, 2026

Ach-Amlodipine · DIN 02419564 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Amlodipine · DIN 02419564 Manufacturer: Accord Healthcare Inc.; listing date 2019-01-31 Daily cost (source): $0.1343 Health Canada: Marketed since 2022-09-13 · brand ACH-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ach-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02419564)

Source record
DIN 02419564: Ach-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id ACH Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419564 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90418
Interchangeable products
Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended September 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02419564
Shortage record checked October 6, 2026

Act Amlodipine · DIN 02297485 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Amlodipine · DIN 02297485 Manufacturer: Teva Canada Limited; listing date 2009-09-30 Daily cost (source): $0.1343 Health Canada: Marketed since 2024-11-08 · brand TEVA-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Act Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02297485)

Source record
DIN 02297485: Act Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297485 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78283
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: Reversed (report reversed by the reporter); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297485
Shortage record checked October 6, 2026

Amlodipine · DIN 02331284 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Amlodipine · DIN 02331284 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Daily cost (source): $0.1343 Health Canada: Marketed since 2022-09-01 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02331284)

Source record
DIN 02331284: Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id SAI Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02331284 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81699
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended August 18, 2017); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02331284
Shortage record checked October 6, 2026

Amlodipine · DIN 02385791 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Amlodipine · DIN 02385791 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Daily cost (source): $0.1343 Health Canada: Marketed since 2016-09-28 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385791)

Source record
DIN 02385791: Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id SIV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385791 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87141
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385791
Shortage record checked October 6, 2026

Amlodipine · DIN 02429217 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Amlodipine · DIN 02429217 Manufacturer: Jamp Pharma Corporation; listing date 2015-01-28 Daily cost (source): $0.1343 Health Canada: Marketed since 2021-02-17 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02429217)

Source record
DIN 02429217: Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02429217 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91365
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429217
Shortage record checked October 6, 2026

Apo-Amlodipine · DIN 02273373 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Amlodipine · DIN 02273373 Manufacturer: Apotex Inc.; listing date 2009-09-30 Daily cost (source): $0.1343 Health Canada: Marketed since 2009-07-09 · brand APO-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02273373)

Source record
DIN 02273373: Apo-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02273373 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75886
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended September 3, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02273373
Shortage record checked October 6, 2026

Auro-Amlodipine · DIN 02397072 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Amlodipine · DIN 02397072 Manufacturer: Auro Pharma Inc.; listing date 2013-04-30 Daily cost (source): $0.1343 Health Canada: Marketed since 2013-02-12 · brand AURO-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02397072)

Source record
DIN 02397072: Auro-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id AUR Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02397072 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88206
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended June 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397072
Shortage record checked October 6, 2026

Bio-Amlodipine · DIN 02392135 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Amlodipine · DIN 02392135 Manufacturer: Biomed Pharma; listing date 2026-09-29 Daily cost (source): $0.1343 Health Canada: Marketed since 2013-01-15 · brand BIO-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Bio-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02392135)

Source record
DIN 02392135: Bio-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id BMP Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02392135 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87742
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended October 25, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392135
Shortage record checked October 6, 2026

Jamp-Amlodipine · DIN 02357194 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Amlodipine · DIN 02357194 Manufacturer: Jamp Pharma Corporation; listing date 2012-02-29 Daily cost (source): $0.1343 Health Canada: Marketed since 2025-04-04 · brand JAMP-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357194)

Source record
DIN 02357194: Jamp-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357194 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84232
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357194
Shortage record checked October 6, 2026

M-Amlodipine · DIN 02468026 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amlodipine · DIN 02468026 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Daily cost (source): $0.1343 Health Canada: Marketed since 2017-12-14 · brand M-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02468026)

Source record
DIN 02468026: M-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MAT Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02468026 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95638
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468026
Shortage record checked October 6, 2026

Mar-Amlodipine Tablets · DIN 02371715 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Amlodipine Tablets · DIN 02371715 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19 Daily cost (source): $0.1343 Health Canada: Marketed since 2021-08-06 · brand MAR-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Amlodipine Tablets: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02371715)

Source record
DIN 02371715: Mar-Amlodipine Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MAR Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02371715 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85685
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mint-Amlodipine · DIN 02362651 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended September 27, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371715
Shortage record checked October 6, 2026

Mint-Amlodipine · DIN 02362651 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Amlodipine · DIN 02362651 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2011-08-04 Daily cost (source): $0.1343 Health Canada: Marketed since 2011-02-16 · brand MINT-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Amlodipine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1343). What the ministry pays, not the patient.

Ministry pays: $0.1343 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02362651)

Source record
DIN 02362651: Mint-Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MIN Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1343; ministry $0.1343 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02362651 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84766
Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343 Act Amlodipine · DIN 02297485 · $0.1343 Amlodipine · DIN 02331284 · $0.1343 Amlodipine · DIN 02385791 · $0.1343 Amlodipine · DIN 02429217 · $0.1343 Apo-Amlodipine · DIN 02273373 · $0.1343 Auro-Amlodipine · DIN 02397072 · $0.1343 Bio-Amlodipine · DIN 02392135 · $0.1343 Gd-Amlodipine · DIN 02280132 · $0.1343 Jamp-Amlodipine · DIN 02357194 · $0.1343 M-Amlodipine · DIN 02468026 · $0.1343 Mar-Amlodipine Tablets · DIN 02371715 · $0.1343 Mylan-Amlodipine · DIN 02272113 · $0.1343 NRA-Amlodipine · DIN 02476460 · $0.1343 Norvasc · DIN 00878928 · $0.1343 PMS-Amlodipine · DIN 02284065 · $0.1343 PRZ-Amlodipine · DIN 02522519 · $0.1343 Ran-Amlodipine · DIN 02321858 · $0.1343 Ratio-Amlodipine · DIN 02259605 · $0.1343 Sandoz Amlodipine · DIN 02284383 · $0.1343 Septa-Amlodipine · DIN 02357712 · $0.1343 Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended January 10, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02362651
Shortage record checked October 6, 2026

Ach-Amlodipine · DIN 02419556 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ach-Amlodipine · DIN 02419556 Manufacturer: Accord Healthcare Inc.; listing date 2025-09-29 Health Canada: Marketed since 2023-02-22 · brand ACH-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02419556)

Source record
DIN 02419556: Ach-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id ACH Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419556 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90417
Interchangeable products
Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended August 9, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02419556
Shortage record checked October 6, 2026

Amlodipine · DIN 02385783 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Amlodipine · DIN 02385783 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-02-28 Health Canada: Marketed since 2016-09-28 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385783)

Source record
DIN 02385783: Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385783 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87140
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385783
Shortage record checked October 6, 2026

Amlodipine · DIN 02478587 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Amlodipine · DIN 02478587 Manufacturer: Sanis Health Inc.; listing date 2025-03-31 Health Canada: Marketed since 2023-04-07 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02478587)

Source record
DIN 02478587: Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02478587 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96905
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478587
Shortage record checked October 6, 2026

Amlodipine · DIN 02492199 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Amlodipine · DIN 02492199 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-08-11 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02492199)

Source record
DIN 02492199: Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02492199 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98218
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492199
Shortage record checked October 6, 2026

Bio-Amlodipine · DIN 02392127 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Bio-Amlodipine · DIN 02392127 Manufacturer: Biomed Pharma; listing date 2026-09-29 Health Canada: Marketed since 2013-01-15 · brand BIO-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02392127)

Source record
DIN 02392127: Bio-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id BMP Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02392127 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87741
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended September 20, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392127
Shortage record checked October 6, 2026

Jamp-Amlodipine · DIN 02357186 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Amlodipine · DIN 02357186 Manufacturer: Jamp Pharma Corporation; listing date 2025-06-30 Health Canada: Marketed since 2021-04-21 · brand JAMP-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357186)

Source record
DIN 02357186: Jamp-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357186 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84231
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended April 21, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357186
Shortage record checked October 6, 2026

M-Amlodipine · DIN 02468018 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
M-Amlodipine · DIN 02468018 Manufacturer: Mantra Pharma Inc.; listing date 2025-04-30 Health Canada: Marketed since 2018-03-07 · brand M-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02468018)

Source record
DIN 02468018: M-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id MAT Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02468018 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95637
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468018
Shortage record checked October 6, 2026

Mar-Amlodipine · DIN 02371707 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mar-Amlodipine · DIN 02371707 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-03-31 Health Canada: Marketed since 2021-08-06 · brand MAR-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02371707)

Source record
DIN 02371707: Mar-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id MAR Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02371707 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85684
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended September 12, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371707
Shortage record checked October 6, 2026

PMS-Amlodipine · DIN 02295148 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Amlodipine · DIN 02295148 Manufacturer: Pharmascience Inc.; listing date 2025-02-28 Health Canada: Marketed since 2009-07-15 · brand PMS-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02295148)

Source record
DIN 02295148: PMS-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id PMS Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295148 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78046
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended November 13, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295148
Shortage record checked October 6, 2026

PRZ-Amlodipine · DIN 02522500 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PRZ-Amlodipine · DIN 02522500 Manufacturer: Pharmaris Canada Inc.; listing date 2026-01-30 Health Canada: Marketed since 2022-09-21 · brand PRZ-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02522500)

Source record
DIN 02522500: PRZ-Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id PRZ Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02522500 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101162
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522500
Shortage record checked October 6, 2026

Sandoz Amlodipine · DIN 02330474 · 2.5 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Amlodipine · DIN 02330474 Manufacturer: Sandoz Canada Inc.; listing date 2024-12-30 Health Canada: Marketed since 2009-08-05 · brand SANDOZ AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02330474)

Source record
DIN 02330474: Sandoz Amlodipine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3328; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02330474 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81620
Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded Amlodipine · DIN 02385783 · not recorded Amlodipine · DIN 02478587 · not recorded Amlodipine · DIN 02492199 · not recorded Bio-Amlodipine · DIN 02392127 · not recorded Jamp-Amlodipine · DIN 02357186 · not recorded M-Amlodipine · DIN 02468018 · not recorded Mar-Amlodipine · DIN 02371707 · not recorded Norvasc · DIN 00878901 · not recorded PMS-Amlodipine · DIN 02295148 · not recorded PRZ-Amlodipine · DIN 02522500 · not recorded
Shortage status: resolved shortage (ended October 10, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330474
Shortage record checked October 6, 2026

Other products in the same Health Canada class (C08CA): coverage varies; not interchangeable

  • Felodipine (Plendil): general benefit, not a benefit
  • Nifedipine: general benefit, not a benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:04 Cardiac Drugs

NIFEDIPINE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 5mg, 10mg · Cap

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors

Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:06 Antilipemic Drugs

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 84 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors

Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

NIFEDIPINE

· 4 products · General benefit (3), Listed, not a benefit (1) · strengths: 30mg, 60mg · ER Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension, stable angina
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph DILTIAZEM HCL · General benefit (91), Listed, not a benefit (2) 1 INDICATIONS AA-DILTIAZ (diltiazem hydrochloride) is indicated for: • Angina ▪ AA-DILTIAZ (diltiazem hydrochloride) tablets may be used in the management of angina resulting from coronary artery spasm. ▪ AA-DILTIAZ tablets are indicated for the management of chronic stable angina (effort- associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. PM: https://pdf.hres.ca/dpd_pm/00082380.PDF; date DEC 31, 1988; DIN 00771376; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. Combination of NORVASC with a diuretic, a beta-blocking agent, or an angiotensin converting enzyme inhibitor has been found to be compatible and showed additive antihypertensive effect. • Chronic Stable Angina NORVASC is indicated for the management of chronic stable angina (effort-associated angina) in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. NORVASC may be tried in combination with beta-blockers in chronic stable angina in patients with normal ventricular function. When such concomitant therapy is introduced, care must be taken to monitor blood pressure closely since hypotension can occur from the combined effects of the drugs. 1.1 Pediatrics Pediatrics (6 – 17 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NORVASC in pediatric patients has been established. Therefore, Health Canada has aut… https://pdf.hres.ca/dpd_pm/00071908.PDF PM date: AUG 02, 2023 Source product: NORVASC; DIN 00878928; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS CADUET (amlodipine besylate/atorvastatin calcium) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate, specifically, patients at cardiovascular risk. CADUET is not for initial therapy. The dose of CADUET should be determined by the titration of individual components (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CADUET in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. However, there have been studies using amlodipine or atorvastatin only in pediatrics (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00081162.PDF PM date: JUL 23, 2025 Source product: CADUET; DIN 02273233; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications VIACORAM (perindopril arginine and amlodipine) is indicated for: • The treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. • VIACORAM 3.5 mg/2.5 mg is indicated for initial therapy in patients with mild to moderate essential hypertension. • VIACORAM is not indicated for switching therapy from the individual drugs currently on the market (perindopril as erbumine or arginine salt, amlodipine) (see 4 Dosage and Administration ). 1.1. Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years): VIACORAM is not indicated for the initiation of treatment in elderly patients. There is no sufficient clinical experience to justify the use in the elderly (> 65 years). https://pdf.hres.ca/dpd_pm/00085937.PDF PM date: 2026-08-27 Source product: VIACORAM; DIN 02451530; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS TWYNSTA (telmisartan/amlodipine besylate) is indicated for: • treatment of mild to moderate essential hypertension for whom combination therapy with telmisartan and amlodipine is appropriate. TWYNSTA is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TWYNSTA in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (> 65 years of age): No dose adjustment is necessary for geriatric patients. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out. https://pdf.hres.ca/dpd_pm/00077924.PDF PM date: AUG 11, 2011 Source product: TWYNSTA; DIN 02371022; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Ach-Amlodipine, Amlodipine, Bio-Amlodipine, Jamp-Amlodipine, M-Amlodipine, Mar-Amlodipine, PMS-Amlodipine, PRZ-Amlodipine, Sandoz Amlodipine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026